Clovis Oncology (CLVS) Stock: The Low Down On Approval

Clovis Oncology (NASDAQ:CLVS) On Monday, Clovis Oncology stock closed higher by 9% after it announced that the FDA had approved its drug. The drug in question is known as rucaparib – to be marketed as Rubraca. This was for early approval of rucaparib, which is used to treat patients with advanced ovarian cancer. The stock … Read more

Biotech Stock News (RXII) (CLVS) (AZN)

Rxi Pharmaceuticals (NASDAQ:RXII) On May 3, 2016 Rxi Pharmaceuticals announced that it had entered into a license agreement with Thera NeuroPharma for the treatment of ALS or Lou Gherig’s Disease. ALS stands for amyotrophic lateral sclerosis, and is a debilitating disease where nerves in the muscles breakdown reducing/eliminating movement. Rxi entered the agreement with this … Read more

Biotech Stock News (CLVS)(SNTA)

Clovis Oncology (NASDAQ:CLVS) On Tuesday April 13, 2016 Clovis Oncology announced that the FDA advisory panel concluded that the company’s drug, Rociletinib, had insufficient data to warrant approval. Not only did the FDA panel advise against approval, it shot down the drug with a vote of 12 “against and 1 “for” approval. This was the … Read more

Biotech Stock News (KBIO) (SNY) (CLVS) (AZN) (VRTX)

KaloBios Pharmaceuticals (NASDAQ:KBIO) Last week I wrote how Kalobios was winding down its operations and was looking to put itself up for sale. In an unforeseen event, Martin Shkreli took a big investment in the company sending the share price higher. Before I go any further let me provide a little backstory so that everyone … Read more

Clovis Oncology (CLVS) Stock | Why I’m Not Concerned About Declines

Clovis Oncology Inc (NASDAQ: CLVS) Clovis Oncology is trading relatively low today after climbing yesterday. However, I’m not too concerned about the declines. As a matter of fact, I think what we’re seeing is very natural and will lead to more upward movement. Today, we’ll discuss the news that caused the company’s stock to climb … Read more

Clovis Oncology Stock | Climbing On Upgrade

Clovis Oncology Inc (NASDAQ: CLVS) If you’ve read my previous posts about Goldman Sachs, you know that I’m not a big fan of the company, nor their analysts. Nonetheless, everyone is talking about their most recent upgrade, and personally, I think they got it right. Earlier today, Terence Flynn, a Goldman Sachs analysts upgraded CLVS … Read more